个人简历
2000 – 2004年， 四川大学华西药学院，理学学士 2004 – 2007年，四川大学华西药学院，理学硕士 2007 – 2012年，美国威斯康辛大学-麦迪逊分校药学院，博士学位 2012 – 2014年，美国威斯康辛大学-麦迪逊分校生物医学工程系，从事博士后研究 2014年3月至今，四川大学华西药学院药剂学系，副教授
研究领域
新型生物材料的设计、合成及在构建递药载体中的应用和评价
近期论文
1.Wang Y, Gong T, Zhang Z, Fu Y*. Matrix stiffness differentially regulates cellular uptake behavior of nanoparticles in two breast cancer cell lines. ACS Appl Mater Interfaces 2017, 9(31), 25915-25928. 2.Zhou X, Qin XY, Gong T, Zhang Z, Fu Y*. D-Fructose modification enhanced internalization of mixed micelles in breast cancer cells via GLUT5 transporters. Macromol Biosci 2017, 17(7), 1600529. 3.Luo Shi, Li PW, Du ZW, Hu X, Fu Y*, Zhang ZR*. N,N-dimethyl tertiary amino group mediated dual pancreas- and lung-targeting therapy against acute pancreatitis. Mol Pharm 2017,14(5),1771-1781. 4.Wang XY, Qi BW, Su HF, Li JB, Sun X, He Q, Fu Y*, Zhang ZR*. Pyrilamine-sensitive proton-coupled organic cation (H+/OC) antiporter for brain-specific drug delivery. J Control Rel 2017, 254, 34-43. 5.Zhou ML, Li JB, Li CH, Guo L, Wang XY, He Q, Fu Y*, Zhang ZR*. Tertiary amine mediated targeted therapy against metastatic lung cancer. J Control Rel 2016, 241, 81-93 6.Cao X, Zhou X, Wang Y, Gong T, Zhang ZR, Liu RH, Fu Y*. Diblock- and triblock-copolymer based mixed micelles with high tumor penetration in vitro and in vivo. J Mater Chem B 2016, 4, 3216-3224. (Hot paper) 7.Zhou X, Liu RH, Qin S, Yu RL, Fu Y*. Current Status and future directions of nanoparticulate strategy for cancer immunotherapy. Current Drug Metabolism 2016,17(8),755-762. 8.Wang MX, Shan FY, Zou Y, Sun X, Zhang ZR, Fu Y*, Gong T*. Pharmacokinetic and pharmacodynamics study of a phospholipid-based phase separation gel for once a month administration of octreotide. J Control Rel 2016, 230, 45-56. 9.Li WH, Yi XL, Liu X, Zhang ZR, Fu Y*, Gong T*. Hyaluronic acid ion-pairing nanoparticles for targeted tumor therapy. J Control Rel 2016, 225, 170-182. 10.Hu M, Zhang Y, Xiang NX, Zhong Y, Gong T, Zhang ZR, Fu Y*. Long-acting phospholipid gel of exenatide for long-term therapy of type II diabetes. Pharm Res 2016, pp1-9 11.Yi XL, Lian XH, Dong JX, Wan ZY, Xia CY, Song X, Fu Y*, Gong T*, Zhang ZR. Co-delivery of pirarubicin and paclitaxel by human serum albumin nanoparticles to enhance antitumor effect and reduce systemic toxicity in breast cancers. Mol Pharm 2015, 12, 4085-4098. 12.He XY, Xiang NX, Zhang JJ, Zhou J, Fu Y*, Gong T*, Zhang ZR. Encapsulation of teniposide into albumin nanoparticles with greatly lowered toxicity and enhanced antitumor activity. Int J Pharm 2015, 487, 250-259. 13.Cao X, Luo JW, Gong T, Zhang ZR, Sun X, Fu Y*. Coencapsulated doxorubicin and bromotetrandrine lipid nanoemulsion in reversing multidrug resistance in breast cancer in vitro and in vivo. Mol Pharm 2015, 12, 274-286.
